Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 35.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 660,639 shares of the company's stock after selling 367,985 shares during the period. D. E. Shaw & Co. Inc. owned 0.13% of Elanco Animal Health worth $8,000,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of ELAN. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $29,000. Jones Financial Companies Lllp grew its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after buying an additional 2,059 shares during the period. SRS Capital Advisors Inc. grew its stake in shares of Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares during the period. MRP Capital Investments LLC purchased a new stake in Elanco Animal Health during the 4th quarter worth $61,000. Finally, Blue Trust Inc. boosted its position in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after purchasing an additional 1,894 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction on Friday, March 7th. The shares were bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the acquisition, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. This represents a 10.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.89% of the stock is currently owned by insiders.

Elanco Animal Health Trading Up 0.5%

Elanco Animal Health stock opened at $12.95 on Friday. The firm has a 50 day simple moving average of $10.05 and a 200-day simple moving average of $11.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market capitalization of $6.43 billion, a PE ratio of 32.38, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period last year, the firm posted $0.34 earnings per share. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. Finally, Piper Sandler dropped their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $15.00.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.